A detailed history of First Trust Advisors LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 2,662 shares of MDGL stock, worth $807,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,662
Holding current value
$807,890
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$212.22 - $292.96 $564,929 - $779,859
2,662 New
2,662 $564,000
Q1 2021

May 14, 2021

SELL
$108.54 - $125.2 $356,662 - $411,407
-3,286 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$110.06 - $133.7 $133,502 - $162,178
1,213 Added 58.51%
3,286 $365,000
Q3 2020

Nov 05, 2020

BUY
$99.78 - $124.21 $206,843 - $257,487
2,073 New
2,073 $246,000
Q4 2018

Feb 07, 2019

SELL
$94.77 - $215.54 $113,060 - $257,139
-1,193 Closed
0 $0
Q3 2018

Oct 25, 2018

BUY
$207.3 - $300.31 $247,308 - $358,269
1,193 New
1,193 $255,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.19B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.